

# Central lab Services Clinical Trial Lab Services - Company Evaluation Report, 2024

<https://marketpublishers.com/r/C9D872977B20EN.html>

Date: August 2025

Pages: 114

Price: US\$ 2,650.00 (Single User License)

ID: C9D872977B20EN

## Abstracts

The Central Lab Services Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Central Lab Services. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 108 companies, of which the Top 11 Central Lab Services Companies were categorized and recognized as quadrant leaders.

Central Lab Services provide standardized, high-quality laboratory testing for pharmaceutical and biotech companies conducting clinical trials across multiple locations. Instead of relying on various local labs with different standards and equipment, all patient samples from trial sites worldwide are shipped to a single, central laboratory. This facility offers a comprehensive menu of services, including safety testing, complex biomarker analysis, sample management, and harmonized data reporting. This centralized approach ensures consistency, accuracy, and data integrity, which are essential for evaluating a drug's safety and efficacy.

The market is driven by the increasing number, complexity, and globalization of clinical trials. As research focuses more on biologics, personalized medicine, and rare diseases, the need for specialized and esoteric testing grows. Pharmaceutical companies increasingly outsource these functions to central labs to leverage their expertise, advanced technology, and global logistics networks, thereby reducing fixed costs and streamlining trial management. The rigorous demand from regulatory bodies like the FDA and EMA for high-quality, standardized data to support drug approval applications makes central labs an indispensable partner in drug development.

However, the industry faces considerable challenges. Managing the complex global

logistics of time- and temperature-sensitive biological samples is a major operational hurdle fraught with risk. Adhering to a patchwork of different international regulations regarding data privacy and sample shipment adds further complexity. The high cost of advanced testing, particularly for genomics and specialized biomarkers, can be substantial. Moreover, the market is highly competitive, putting pressure on pricing and forcing providers to continuously invest in new technologies to maintain a competitive edge.

The 360 Quadrant maps the Central Lab Services companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Central Lab Services quadrant. The top criteria for product footprint evaluation included Phase (Phase I, Phase II, Phase III, Phase IV), Therapeutic Area (Oncology, Infectious Diseases, Neurology, Cardiology, Other Therapeutic Areas), Service Type (Safety Testing, Immunology, Genetic Testing, Coagulation Testing, Pathology Testing, Biomarkers, Companion Diagnostics, Other Tests), Modality (Small Molecules, Biologics (Monoclonal Antibodies, Vaccines, Other Therapeutic Products), Cell & Gene Therapy, Medical Devices & IVD Devices), End User (Pharmaceutical & Biopharmaceutical Companies, CROs, Medical Device Companies, Other End Users).

Key Players:

Major vendors in the Central Lab Services market are Thermo Fisher Scientific Inc. (US), IQVIA (US), and ICON plc (Ireland).

The key strategies major vendors implement in the Central Lab Services market are partnerships, collaborations, product launches, and product enhancements.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is the undisputed world leader in serving science, offering an unparalleled portfolio of analytical instruments, laboratory equipment, and biopharma services. Through its industry-leading brands, the company provides foundational tools for research, diagnostics, and manufacturing. Strategically, Thermo Fisher acts as an end-to-end partner for the pharmaceutical industry, supporting customers from initial discovery to commercial production. By focusing on high-growth areas like cell and gene therapy, expanding its digital science platforms, and capitalizing on its vast global scale, the company maintains its dominant position in the life sciences ecosystem.

## IQVIA

IQVIA is a global leader in using data and science to help healthcare clients find better solutions for patients. Formed from the merger of IMS Health and Quintiles, its unique strength lies in combining advanced data analytics with deep clinical research expertise. IQVIA's strategy is to power smarter, faster drug development by leveraging its vast healthcare data and AI-driven CORE™ platform. By providing data-rich insights for trial design, patient recruitment, and real-world evidence studies, the company solidifies its position as an indispensable partner for the global life sciences industry.

## ICON plc

ICON plc is a global leader in the contract research organization (CRO) industry, providing comprehensive drug and device development services. Following its transformative acquisition of PRA Health Sciences, the company boasts immense scale and a fully integrated service offering for its pharma and biotech clients. Strategically, ICON focuses on delivering patient-centric and decentralized clinical trials, leveraging technology to improve access and efficiency. By combining its deep therapeutic expertise with a commitment to data-driven solutions and operational excellence, ICON maintains its position as a top-tier partner in advancing global healthcare innovation.

## Contents

### 1 INTRODUCTION

#### 1.1 MARKET DEFINITION

#### 1.2 STAKEHOLDERS

### 2 EXECUTIVE SUMMARY

### 3 MARKET OVERVIEW

#### 3.1 INTRODUCTION

#### 3.2 MARKET DYNAMICS

##### 3.2.1 DRIVERS

3.2.1.1 Increasing number of clinical trials

3.2.1.2 Rising investments in research & development

3.2.1.3 Growing prevalence of rare diseases

3.2.1.4 Favorable government initiatives

##### 3.2.2 RESTRAINTS

3.2.2.1 High costs associated with clinical trials

3.2.2.2 Shortage of skilled professionals

##### 3.2.3 OPPORTUNITIES

3.2.3.1 Emerging markets worldwide

3.2.3.2 Decentralized and virtual clinical trials

##### 3.2.4 CHALLENGES

3.2.4.1 Regulatory complexities

3.2.4.2 Limited patient diversity

3.2.4.3 Cybersecurity and intellectual property concerns

#### 3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

#### 3.4 VALUE CHAIN ANALYSIS

##### 3.4.1 RESOURCE ACQUISITION AND PREPARATION

##### 3.4.2 CLINICAL TRIAL EXECUTION

##### 3.4.3 DATA REPORTING AND RESULT SUBMISSION

##### 3.4.4 PROMOTION AND REGULATORY FILING

#### 3.5 ECOSYSTEM ANALYSIS

#### 3.6 TECHNOLOGY ANALYSIS

##### 3.6.1 KEY TECHNOLOGIES

3.6.1.1 Enzyme-linked immunosorbent assay

##### 3.6.2 ADJACENT TECHNOLOGIES

- 3.6.2.1 Next-generation sequencing
- 3.7 KEY CONFERENCES AND EVENTS, 2025–2026
- 3.8 PORTER'S FIVE FORCES ANALYSIS
  - 3.8.1 THREAT OF NEW ENTRANTS
  - 3.8.2 THREAT OF SUBSTITUTES
  - 3.8.3 BARGAINING POWER OF SUPPLIERS
  - 3.8.4 BARGAINING POWER OF BUYERS
  - 3.8.5 INTENSITY OF COMPETITIVE RIVALRY
- 3.9 IMPACT OF AI/GENERATIVE AI ON CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
  - 3.9.1 INTRODUCTION
  - 3.9.2 MARKET POTENTIAL OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES
  - 3.9.3 AI USE CASES
  - 3.9.4 FUTURE OF GENERATIVE AI IN CLINICAL TRIAL LAB ECOSYSTEM

## **4 COMPETITIVE LANDSCAPE**

- 4.1 OVERVIEW
- 4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  - 4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET
- 4.3 REVENUE ANALYSIS, 2020?2024
- 4.4 MARKET SHARE ANALYSIS, 2024
- 4.5 COMPANY VALUATION AND FINANCIAL METRICS
- 4.6 BRAND/PRODUCT COMPARISON
- 4.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  - 4.7.1 STARS
  - 4.7.2 EMERGING LEADERS
  - 4.7.3 PERVASIVE PLAYERS
  - 4.7.4 PARTICIPANTS
  - 4.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - 4.7.5.1 Company footprint
    - 4.7.5.2 Region footprint
    - 4.7.5.3 Product type footprint
    - 4.7.5.4 Therapeutic area footprint
    - 4.7.5.5 Phase footprint
- 4.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 4.8.1 PROGRESSIVE COMPANIES

- 4.8.2 RESPONSIVE COMPANIES
- 4.8.3 DYNAMIC COMPANIES
- 4.8.4 STARTING BLOCKS
- 4.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  - 4.8.5.1 Detailed list of key startups/SMEs
  - 4.8.5.2 Competitive benchmarking of key startups/SMEs
- 4.9 COMPETITIVE SCENARIO
  - 4.9.1 PRODUCT LAUNCHES
  - 4.9.2 DEALS
  - 4.9.3 EXPANSIONS
  - 4.9.4 OTHER DEVELOPMENTS

## **5 COMPANY PROFILES**

### **5.1 KEY PLAYERS**

#### **5.1.1 THERMO FISHER SCIENTIFIC INC.**

- 5.1.1.1 Business overview
- 5.1.1.2 Products/Services offered
- 5.1.1.3 Recent developments
  - 5.1.1.3.1 Product launches
  - 5.1.1.3.2 Deals
  - 5.1.1.3.3 Expansions
- 5.1.1.4 MnM view
  - 5.1.1.4.1 Key strengths
  - 5.1.1.4.2 Strategic choices
  - 5.1.1.4.3 Weaknesses and competitive threats

#### **5.1.2 IQVIA**

- 5.1.2.1 Business overview
- 5.1.2.2 Products/Services offered
- 5.1.2.3 Recent developments
  - 5.1.2.3.1 Product launches
  - 5.1.2.3.2 Deals
- 5.1.2.4 MnM view
  - 5.1.2.4.1 Right to win
  - 5.1.2.4.2 Strategic choices
  - 5.1.2.4.3 Weaknesses and competitive threats

#### **5.1.3 ICON PLC**

- 5.1.3.1 Business overview
- 5.1.3.2 Products/Services offered

- 5.1.3.3 Recent developments
  - 5.1.3.3.1 Product launches
  - 5.1.3.3.2 Deals
- 5.1.3.4 MnM view
  - 5.1.3.4.1 Right to win
  - 5.1.3.4.2 Strategic choices
  - 5.1.3.4.3 Weaknesses and competitive threats
- 5.1.4 CHARLES RIVER LABORATORIES
  - 5.1.4.1 Business overview
  - 5.1.4.2 Products/Services offered
  - 5.1.4.3 Recent developments
    - 5.1.4.3.1 Deals
    - 5.1.4.3.2 Expansions
  - 5.1.4.4 MnM view
    - 5.1.4.4.1 Right to win
    - 5.1.4.4.2 Strategic choices
    - 5.1.4.4.3 Weaknesses and competitive threats
- 5.1.5 LABCORP
  - 5.1.5.1 Business overview
  - 5.1.5.2 Products/Services offered
  - 5.1.5.3 Recent developments
    - 5.1.5.3.1 Product launches
    - 5.1.5.3.2 Deals
    - 5.1.5.3.3 Expansions
    - 5.1.5.3.4 Other developments
  - 5.1.5.4 MnM view
    - 5.1.5.4.1 Key strengths
    - 5.1.5.4.2 Strategic choices
    - 5.1.5.4.3 Weaknesses and competitive threats
- 5.1.6 QUEST DIAGNOSTICS
  - 5.1.6.1 Business overview
  - 5.1.6.2 Products/Services offered
  - 5.1.6.3 Recent developments
    - 5.1.6.3.1 Deals
- 5.1.7 MEDPACE
  - 5.1.7.1 Business overview
  - 5.1.7.2 Products/Services offered
  - 5.1.7.3 Recent developments
    - 5.1.7.3.1 Expansions

## 5.1.8 FRONTAGE LABS

5.1.8.1 Business overview

5.1.8.2 Products/Services offered

## 5.1.9 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA

5.1.9.1 Business overview

5.1.9.2 Products/Services offered

5.1.9.3 Recent developments

5.1.9.3.1 Deals

## 5.1.10 EUROFINS SCIENTIFIC

5.1.10.1 Business overview

5.1.10.2 Products/Services offered

5.1.10.3 Recent developments

5.1.10.3.1 Deals

## 5.1.11 REPROCELL INC.

5.1.11.1 Business overview

5.1.11.2 Products/Services offered

5.1.11.3 Recent developments

5.1.11.3.1 Deals

## 5.1.12 ACM GLOBAL LABORATORIES

5.1.12.1 Business overview

5.1.12.2 Products/Services offered

5.1.12.3 Recent developments

5.1.12.3.1 Deals

## 5.2 OTHER PLAYERS

5.2.1 WORLDWIDE CLINICAL TRIALS

5.2.2 VERSITI

5.2.3 CTI CLINICAL TRIAL & CONSULTING

5.2.4 CLARITY LABORATORIES, INC

5.2.5 NOVOTECH

5.2.6 ARUP LABORATORIES

5.2.7 PRECISION MEDICINE GROUP

5.2.8 BIOAGILYTIX LABS

5.2.9 CERBA HEALTHCARE

5.2.10 ALMAC GROUP

5.2.11 MLM MEDICAL LABS

5.2.12 SALVUS BIORESEARCH SOLUTIONS LLP

5.2.13 UNILABS

## 6 APPENDIX

## 6.1 RESEARCH METHODOLOGY

### 6.1.1 RESEARCH DATA

#### 6.1.1.1 Secondary data

#### 6.1.1.2 Primary data

### 6.1.2 RESEARCH ASSUMPTIONS

### 6.1.3 RESEARCH LIMITATIONS

### 6.1.4 RISK ASSESSMENT

## 6.2 COMPANY EVALUATION MATRIX: METHODOLOGY

## 6.3 AUTHOR DETAILS

## List Of Tables

### LIST OF TABLES

TABLE 1 TRADITIONAL VS. VIRTUAL CLINICAL TRIALS

TABLE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
ROLE OF COMPANIES IN ECOSYSTEM

TABLE 3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: KEY  
CONFERENCES AND EVENTS, 2025?2026

TABLE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
PORTER'S FIVE FORCES ANALYSIS

TABLE 5 KEY COMPANIES IMPLEMENTING AI

TABLE 6 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CENTRAL  
LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2022–2025

TABLE 7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
DEGREE OF COMPETITION

TABLE 8 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
REGION FOOTPRINT

TABLE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
PRODUCT TYPE FOOTPRINT

TABLE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
THERAPEUTIC AREA FOOTPRINT

TABLE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
PHASE FOOTPRINT

TABLE 12 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
DETAILED LIST OF KEY STARTUPS/SMES

TABLE 13 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 14 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025

TABLE 15 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
DEALS, JANUARY 2022–JANUARY 2025

TABLE 16 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
EXPANSIONS, JANUARY 2022–JANUARY 2025

TABLE 17 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025

TABLE 18 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW

TABLE 19 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED

TABLE 20 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY  
2022–JANUARY 2025

TABLE 21 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–JANUARY 2025

TABLE 22 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–JANUARY 2025

TABLE 23 IQVIA: COMPANY OVERVIEW

TABLE 24 IQVIA: PRODUCTS/SERVICES OFFERED

TABLE 25 IQVIA: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025

TABLE 26 IQVIA: DEALS, JANUARY 2022–JANUARY 2025

TABLE 27 ICON PLC: COMPANY OVERVIEW

TABLE 28 ICON PLC: PRODUCTS/SERVICES OFFERED

TABLE 29 ICON PLC: PRODUCT LAUNCHES, JANUARY 2022–JANUARY 2025

TABLE 30 ICON PLC: DEALS, JANUARY 2022–JANUARY 2025

TABLE 31 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW

TABLE 32 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED

TABLE 33 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025

TABLE 34 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–JANUARY 2025

TABLE 35 LABCORP: COMPANY OVERVIEW

TABLE 36 LABCORP: PRODUCTS/SERVICES OFFERED

TABLE 37 LABCORP: PRODUCTS LAUNCHES, JANUARY 2022–JANUARY 2025

TABLE 38 LABCORP: DEALS, JANUARY 2022–JANUARY 2025

TABLE 39 LABCORP: EXPANSIONS, JANUARY 2022–JANUARY 2025

TABLE 40 LABCORP: OTHER DEVELOPMENTS, JANUARY 2022–JANUARY 2025

TABLE 41 QUEST DIAGNOSTICS: COMPANY OVERVIEW

TABLE 42 QUEST DIAGNOSTICS: PRODUCTS/SERVICES OFFERED

TABLE 43 QUEST DIAGNOSTICS: DEALS, JANUARY 2022–JANUARY 2025

TABLE 44 MEDPACE: COMPANY OVERVIEW

TABLE 45 MEDPACE: PRODUCTS/SERVICES OFFERED

TABLE 46 MEDPACE: EXPANSIONS, JANUARY 2022–JANUARY 2025

TABLE 47 FRONTAGE LABS: COMPANY OVERVIEW

TABLE 48 FRONTAGE LABS: PRODUCTS/SERVICES OFFERED

TABLE 49 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW

TABLE 50 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: PRODUCTS/SERVICES OFFERED

TABLE 51 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: DEALS, JANUARY 2022–JANUARY 2025

TABLE 52 EUROFINS SCIENTIFIC: COMPANY OVERVIEW

TABLE 53 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED

TABLE 54 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–JANUARY 2025

TABLE 55 REPROCELL INC.: COMPANY OVERVIEW

TABLE 56 REPROCELL INC.: PRODUCTS/SERVICES OFFERED

TABLE 57 REPROCELL INC.: DEALS, JANUARY 2022–JANUARY 2025

TABLE 58 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW

TABLE 59 ACM GLOBAL LABORATORIES: PRODUCTS/SERVICES OFFERED

TABLE 60 ACM GLOBAL LABORATORIES: DEALS, JANUARY 2022–JANUARY 2025

TABLE 61 WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW

TABLE 62 VERSITI: COMPANY OVERVIEW

TABLE 63 CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW

TABLE 64 CLARITY LABORATORIES, INC: COMPANY OVERVIEW

TABLE 65 NOVOTECH: COMPANY OVERVIEW

TABLE 66 ARUP LABORATORIES: COMPANY OVERVIEW

TABLE 67 PRECISION MEDICINE GROUP: COMPANY OVERVIEW

TABLE 68 BIOAGILYTIX LABS: COMPANY OVERVIEW

TABLE 69 CERBA HEALTHCARE: COMPANY OVERVIEW

TABLE 70 ALMAC GROUP: COMPANY OVERVIEW

TABLE 71 MLM MEDICAL LABS: COMPANY OVERVIEW

TABLE 72 SALVUS BIORESEARCH SOLUTIONS LLP: COMPANY OVERVIEW

TABLE 73 UNILABS: COMPANY OVERVIEW

TABLE 74 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
RISK ASSESSMENT

## List Of Figures

### LIST OF FIGURES

FIGURE 1 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY PHASE, 2025 VS. 2030 (USD MILLION)

FIGURE 2 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY SERVICE TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 3 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 4 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)

FIGURE 5 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 6 GEOGRAPHICAL SNAPSHOT OF CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET

FIGURE 7 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

FIGURE 9 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: VALUE CHAIN ANALYSIS

FIGURE 10 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: ECOSYSTEM ANALYSIS

FIGURE 11 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 12 AI USE CASES

FIGURE 13 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2024 (USD MILLION)

FIGURE 14 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024

FIGURE 15 RANKING OF KEY PLAYERS IN CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET, 2024

FIGURE 16 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025

FIGURE 17 FINANCIAL METRICS, 2025

FIGURE 18 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: BRAND/PRODUCT COMPARISON

FIGURE 19 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 20 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET: COMPANY FOOTPRINT

FIGURE 21 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:

COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024  
FIGURE 22 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)  
FIGURE 23 IQVIA: COMPANY SNAPSHOT (2024)  
FIGURE 24 ICON PLC: COMPANY SNAPSHOT (2023)  
FIGURE 25 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2023)  
FIGURE 26 LABCORP: COMPANY SNAPSHOT (2024)  
FIGURE 27 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2024)  
FIGURE 28 MEDPACE: COMPANY SNAPSHOT (2024)  
FIGURE 29 FRONTAGE LABS: COMPANY SNAPSHOT (2023)  
FIGURE 30 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY  
SNAPSHOT (2024)  
FIGURE 31 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)  
FIGURE 32 CENTRAL LAB SERVICES/CLINICAL TRIAL LAB SERVICES MARKET:  
RESEARCH DESIGN

## I would like to order

Product name: Central lab Services Clinical Trial Lab Services - Company Evaluation Report, 2024

Product link: <https://marketpublishers.com/r/C9D872977B20EN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C9D872977B20EN.html>